The mutated genes specific to this subtype included genes involved in the JAK/STAT pathway, which have previously been linked with tumour suppression, improved response to immunotherapy and improved prognosis in cancer patients.59 The study also demonstrated that the EBV+/TMB-low tumours were characterised by mutations in DNA repair genes and the MMR pathway, which may enhance the tumour’s sensitivity to chemotherapy, thereby improving patient prognosis. This evidence concerns the gene MRC1 and neoplasm.